A Rare Side Effect Of Hydroxycholoroqine: Acute Generalised Exanthematous Pustulosis Hydroxycholoroqine Induced Cutaneous Lesions / Hidroksiklorokinin Nadir Bir Yan Etkisi: Akut Jeneralize Egzantamatöz Pustulozis

Yıl 2017, Cilt: 39 Sayı: 1, 78 - 80, 07.01.2017

Şule Yaşar Bilge , Tuba Erdoğan

https://doi.org/10.20515/otd.288710

Öz

Abstract:  Hydroxycholoroqine (HCQ) is a widely used drug in treatment of various
rheumatic disease. Even, it is commonly used in treatment of cuteneus
manifestations of lupus sometimes the drug it self can cause cutaneus adverse
effects. Acute generalised exanthematous pustulosis (AGEP) is a rare kind of
dermatosis and herein we report a case who developed AGEP after HCQ usage for
treatment of rheumatoid arthritis.

Keywords: Acute generalized
exanthematous pustulosis, adverse effect, hydroxycholoroqine, dermatosis

 

 

Özet: Hidroksiklorokin (HCQ) pek
çok romatizmal hastalığın tedavisinde yaygın olarak kullanılan bir ilaçtır. Her
ne kadar kendisi lupusun cilt tutulumunda kullanılsa da bazen kendisi kutanöz
yan etkilere sebep olabilir. Akut jeneralize egzantamatöz püstülozis (AGEP)
nadir bir dermatoz türüdür ve burada RA tedavisi için HCQ kullanan ve AGEP
gelişen bir olgudan bahsedilecektir.

Anahtar
Kelimeler: Akut jeneralize
egzantamatöz püstülozis, yan etki, hidroksiklorokin, dermatoz

Anahtar Kelimeler

Acute generalized exanthematous pustulosis, adverse effect, hydroxycholoroqine

Kaynakça

• 1. Seibel, M. M., Smith, D. M., Levesque, L., Borten, M., & Taymor, M. L. (1982). The temporal relationship between the luteinizing hormone surge and human oocyte maturation. American journal of obstetrics and gynecology, 142(5), 568-572.
• 2. Bar-Ami, S., Zlotkin, E., Brandes, J. M., & Itskovitz-Eldor, J. (1994). Failure of meiotic competence in human oocytes. Biology of reproduction, 50(5), 1100-1107.
• 3. Levran, D., Farhi, J., Nahum, H., Glezerman, M., & Weissman, A. (2002). Maturation arrest of human oocytes as a cause of infertility: case report. Human Reproduction, 17(6), 1604-1609.
• 4. Bergère, M., Lombroso, R., Gombault, M., Wainer, R., & Selva, J. (2001). An idiopathic infertility with oocytes metaphase I maturation block Case report. Human Reproduction, 16(10), 2136-2138.
• 5. Gulekli, B., Olgan, S., & Aydiner, F. (2011). In vitro oocyte maturation from unstimulated cycles: does it offer a realistic chance to overcome the problem of repeated oocyte maturation arrest in IVF?. Archives of gynecology and obstetrics, 283(1), 133-134.
• 6. Harrison, K. L., Sherrin, D. A., & Keeping, J. D. (2000). Repeated oocyte maturation block. Journal of assisted reproduction and genetics, 17(4), 231-231.
• 7. ichael Ludwig, M., Doody, K. J., & Doody, K. M. (2003). Use of recombinant human chorionic gonadotropin in ovulation induction. Fertility and sterility, 79(5), 1051-1059.
• 8. GONEN, Y., BALAKIER, H., POWELL, W., & CASPER, R. F. (1990). Use of Gonadotropin-Releasing Hormone Agonist to Trigger Follicular Maturation for in Vitro Fertilization*. The Journal of Clinical Endocrinology & Metabolism, 71(4), 918-922.
• 9. Orvieto, R. (2015). Triggering final follicular maturation-hCG, GnRH-agonist or both, when and to whom?. Journal of ovarian research, 8(1), 1.
• 10. Lin, M. H., Wu, F. S. Y., Lee, R. K. K., Li, S. H., Lin, S. Y., & Hwu, Y. M. (2013). Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles. Fertility and sterility, 100(5), 1296-1302.
• 11. Griffin, D., Feinn, R., Engmann, L., Nulsen, J., Budinetz, T., & Benadiva, C. (2014). Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates. Fertility and sterility, 102(2), 405-409.
• 12. Fritz, M.A. Speroff, L. (2011). Regulation of the Menstrual Cycle: Clinical Gynecologic Endocrinology and Infertility. Philadelphia: Lippincott Williams & Wilkins.
• 13. Segal, S., & Casper, R. F. (1992). Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin for triggering follicular maturation in in vitro fertilization. Fertility and sterility, 57(6), 1254-1258.
• 14. Imoedemhe, D. A., Sigue, A. B., Pacpaco, E. L. A., & Olazo, A. B. (1991). Stimulation of endogenous surge of luteinizing hormone with gonadotropin-releasing hormone analog after ovarian stimulation for in vitro fertilization. Fertility and sterility, 55(2), 328-332.
• 15. Zelinski-Wooten, M. B., Hutchison, J. S., Hess, D. L., Wolf, D. P., & Stouffer, R. L. (1995). Endocrinology: Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin-releasing hormone antagonist-treated monkeys. Human Reproduction, 10(7), 1658-1666.
• 16. Erb, T. M., Vitek, W., & Wakim, A. N. (2010). Gonadotropin-releasing hormone agonist or human chorionic gonadotropin for final oocyte maturation in an oocyte donor program. Fertility and sterility, 93(2), 374-378.
• 17. Fauser, B. C., de Jong, D., Olivennes, F., Wramsby, H., Tay, C., Itskovitz-Eldor, J., & Van Hooren, H. G. (2002). Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. The Journal of Clinical Endocrinology & Metabolism, 87(2), 709-715.
• 18. Humaidan, P., Bredkjær, H. E., Bungum, L., Bungum, M., Grøndahl, M. L., Westergaard, L., & Andersen, C. Y. (2005). GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Human Reproduction, 20(5), 1213-1220.
• 19. Humaidan, P., Bungum, L., Bungum, M., & Andersen, C. Y. (2006). Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reproductive biomedicine online, 13(2), 173-178.